Latest Breaking News On - Allison soss - Page 8 : comparemela.com

Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation

29.06.2022 - Leverages Mindset’s Platform Technology for Efficient Delivery of CNS TherapeuticsTORONTO, June 29, 2022 (GLOBE NEWSWIRE) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development .

Jason atkinsonJames lanthierMckenna millerAllison sossOtsuka pharmaceuticalsStrategic communicationsCorporate developmentMindset pharma incCompany contactStrategic researchMcquade center

Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin

TORONTO, June 22, 2022 (GLOBE NEWSWIRE) Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) , a drug discovery and…

Jason atkinsonJames lanthierAnh dzungMckenna millerDouglas funkAllison sossOtsuka pharmaceuticalsNeurobiology of alcohol labCompany contactMental healthStrategic researchMcquade centerUniversity of torontoStrategic communicationsCampbell family mental health research instituteCorporate development

Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders

10.06.2022 - TORONTO, June 10, 2022 (GLOBE NEWSWIRE) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ( Mindset or the Company ), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic .

Jason atkinsonJames lanthierMckenna millerAllison sossOtsuka pharmaceuticalsStrategic communicationsCorporate developmentMindset pharma incCompany contactStrategic researchMcquade center

Mindset Pharma to Participate in Upcoming Conferences in June 2022

Mindset Pharma to Participate in Upcoming Conferences in June 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesJason atkinsonFiona randallJames lanthierAllison sossAc hotelOtsuka pharmaceuticalsCompany contactMental health disordersMindset pharma incStrategic researchLotte new york palace hotelMental health conferenceMcquade centerStrategic communications

SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination is 53.9 percent compared to 37.2 percent in a checkpoint inhibitor. | May 26, 2022

United statesAngelos stergiouMichaela fawcettJeffreys weberAllison sossRaquel conaLangone healthCompany wilmsGenfleet therapeutics shanghai incMerck co incStrategic communicationsLife sciences group incYork universityMelanoma research program centerPerlmutter cancer centerMemorial sloan kettering cancer center